Lior Shaltiel
Chief Executive Officer NurExone
Dr. Lior Shaltiel is the Chief Executive Officer of NurExone Biologic, a biotechnology company developing exosome-based therapies for spinal cord and central nervous system injuries. He is an entrepreneur and award-winning scientist with multidisciplinary expertise in chemical engineering, molecular biology, pharmacology, electrophysiology, and advanced drug delivery systems. Before joining NurExone, he worked with several nanomedicine and biotech ventures and also served in investment and business development roles within the life sciences sector. Dr. Shaltiel founded and leads the BioMed-MBA program at the Hebrew University of Jerusalem and has played a key role in advancing regenerative medicine and extracellular vesicle therapeutics.
Seminars
- Exploring how investors assess scientific credibility, clinical maturity, and differentiation within a rapidly evolving exosome landscape
- Debating key risk factors including regulatory uncertainty, manufacturing scalability, and reproducibility of exosome-based products
- Identifying investment catalysts such as early clinical readouts, strategic partnerships, and platform validation across multiple indications
